Published :
Tables : 66
Figures : 48
Category : Healthcare
No. of Pages : 236
Report Code : HC-U3303
High Throughput Screening Market is expected to value over USD 24 billion by 2027 end with a CAGR of over 8% during the forecast period 2020 to 2027. Growing financial assistance by private and public organizations for research and development activities, advancements in the high throughput screening technology and increased initiatives taken by biotech and pharma companies for promoting this technology are some of the crucial factors contributing to the growth of the market. High throughput screening is primarily used for conducting different chemical, pharmacological and genetic tests that help in the entire process of drug discovery which involves devices for liquid handling, control software, identification of active compounds, biomolecular and genetic interactions. Additionally, this method helps in screening a variety of compounds up to over 10,000 compounds daily and by using UHTS, it can conduct over 100,000 assays per day. There has been an extensive research conducted by major pharmaceutical companies. For instance, the UK’s Medical Research Council Laboratory of Molecular Biology collaborated with AstraZeneca and UCB in August 2017 for speeding the research of drug discovery by offering their academic research along with industrial expertise and infrastructure. However, a lack of skilled labour shall impede the high throughput screening market growth. Furthermore, the processes of target characterization and selection, compound screening, assay development require a lot of time and are expensive to perform, thereby limiting the growth of the market. Moreover, programs like ‘Toxicology in the 21st Century’, a joint venture of the US FDA, EPA and the US NIH, use automated HTS for testing environmental drugs, chemicals and formulation for an extensive toxicological evaluation and in developing pathways that are associated to the disease and can predict the toxicological levels. Such ventures shall pave way for lucrative opportunities to the proliferation of the market. Market Segmentation: By Products and Services • Products • Services By Technology • Cell-Based Assays - Cell Proliferation Assays - Cell Viability Assays - Cell Cytotoxicity Assays - Cell Death Assays - Other Cell-Based Assays • Lab-on-a-Chips - PDMS - Thermopolymers - Glass - Silicon - Paper • Ultra high throughput Screening - Chip-based Screening - Micro-channel Flow Systems - Plateless Systems - Others • Label-Free Technology - SPR - ITC - Others By Application • Drug Discovery - Medicinal Chemistry - Biology Services - Drug Metabolism and Pharmacokinetics (DMPK) • Chemical Biology Programs - Cellular & Biological Simulation - Disease Modelling - Preclinical Drug Development - Clinical Trials • Cell & Organ-Based Screening - Drug Discovery - Academic Research • Biochemical Screening - Blood and Blood –based Products - Vaccines and Therapeutics - Stem Cells • Biological Active Compound Screening - Target Identification - Primary Screening - Toxicology • Genomics - Diagnostic Application - Precision Medicine • Proteomics - Drug Diagnostics - Precision Medicine • Compound Profiling - Drug Discovery - Cancer/Tumor Profiling - Toxicology By Detection Method • Mass Spectrometry - Surface-based MALDI-MS - LASI-MS Imaging - Injection-based MS - Others • Chromatography - HIC - HPLC - SEC - HPGC - Others • Calorimetry - Rapid Mass Calorimeter - ITC - Nanocalorimetry - Array Calorimetry - Others • X-ray Diffraction - In situ Crystallization - In meso Crystallization - Crystal X-ray Diffraction - Others By End-User • Pharmaceutical and Biotechnology Companies • Academic and Government Institutes • Contract Research Organizations (CRO) • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa The market is classified into products and services, technology, application, end user and region. The products and services segment is fragmented into reagents and assay kits, instruments, software and services. The reagents and assay kits segment held the largest high throughput screening market share and this can be credited to an increased used of assay kits and reactors in HTS method, growing occurrences of chronic diseases, increase in the number of research and development activities by pharmaceutical companies, surging assistance from government through massive funding for research in the life sciences sector. However, the software segment is predicted to showcase significant growth during the forecasted timeframe, and this is due to the soaring automation of HTS and the ease of availability of software tools required for data management. The technology segment is divided into cell-based assay which is further divided into 2D cell culture and 3D cell culture, lab-on-a-chip, ultra-high throughput screening, bioinformatics and label-free technology. The label-free technology is predicted to record the highest growth during the forecasted timeframe, and this is primarily due to advancements that have improved the throughput, cost, sensitivity and data analysis level. Using assays that are biologically relevant is the new high throughput screening market trend which shall provide growth opportunities for the market. The end user segment is fragmented into CROs, academic and government institutes, pharmaceutical and biotech companies and other end users. The pharmaceutical and biotech companies are expected to lead the market, and this is due to the in-depth usage of HTS technology in these companies for application related to drug discovery. Regional Analysis: The North America region is anticipated to dominate the market owing to a rise in the research and development expenditure provided by the pharma and biotech companies and the increased acceptance of HTS in the region. The Asia Pacific region, however, is poised to showcase substantial growth during the forecast period and this can be credited to a soaring expenditure on research and development, increased private-public collaborations and increased export of services offering drug discovery. Competitive Landscape: Some of the key market players are Thermo Fisher Scientific, Agilent Technologies Inc., Danaher , PerkinElmer Inc., Tecan Group Ltd., Axxam S.p.A, Bio-Rad Laboratories Inc, Merck Group KGaA, Hamilton Company, Corning Incorporated, Biotek Instruments Inc., Aurora Biomed Inc. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global high throughput screening market by products and services, by technology, by application, by detection method, by end user and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Growing financial assistance by private and public organizations for research and development activities, advancements in the high throughput screening technology and increased initiatives taken by biotech and pharma companies for promoting this technology are some of the crucial factors contributing to the growth of the market. High throughput screening is primarily used for conducting different chemical, pharmacological and genetic tests that help in the entire process of drug discovery which involves devices for liquid handling, control software, identification of active compounds, biomolecular and genetic interactions. Additionally, this method helps in screening a variety of compounds up to over 10,000 compounds daily and by using UHTS, it can conduct over 100,000 assays per day. There has been an extensive research conducted by major pharmaceutical companies. For instance, the UK’s Medical Research Council Laboratory of Molecular Biology collaborated with AstraZeneca and UCB in August 2017 for speeding the research of drug discovery by offering their academic research along with industrial expertise and infrastructure. However, a lack of skilled labour shall impede the high throughput screening market growth. Furthermore, the processes of target characterization and selection, compound screening, assay development require a lot of time and are expensive to perform, thereby limiting the growth of the market. Moreover, programs like ‘Toxicology in the 21st Century’, a joint venture of the US FDA, EPA and the US NIH, use automated HTS for testing environmental drugs, chemicals and formulation for an extensive toxicological evaluation and in developing pathways that are associated to the disease and can predict the toxicological levels. Such ventures shall pave way for lucrative opportunities to the proliferation of the market.
Market Segmentation:
By Products and Services • Products • Services
By Technology • Cell-Based Assays - Cell Proliferation Assays - Cell Viability Assays - Cell Cytotoxicity Assays - Cell Death Assays - Other Cell-Based Assays • Lab-on-a-Chips - PDMS - Thermopolymers - Glass - Silicon - Paper • Ultra high throughput Screening - Chip-based Screening - Micro-channel Flow Systems - Plateless Systems - Others • Label-Free Technology - SPR - ITC - Others
By Application • Drug Discovery - Medicinal Chemistry - Biology Services - Drug Metabolism and Pharmacokinetics (DMPK) • Chemical Biology Programs - Cellular & Biological Simulation - Disease Modelling - Preclinical Drug Development - Clinical Trials • Cell & Organ-Based Screening - Drug Discovery - Academic Research • Biochemical Screening - Blood and Blood –based Products - Vaccines and Therapeutics - Stem Cells • Biological Active Compound Screening - Target Identification - Primary Screening - Toxicology • Genomics - Diagnostic Application - Precision Medicine • Proteomics - Drug Diagnostics - Precision Medicine • Compound Profiling - Drug Discovery - Cancer/Tumor Profiling - Toxicology
By Detection Method • Mass Spectrometry - Surface-based MALDI-MS - LASI-MS Imaging - Injection-based MS - Others • Chromatography - HIC - HPLC - SEC - HPGC - Others • Calorimetry - Rapid Mass Calorimeter - ITC - Nanocalorimetry - Array Calorimetry - Others • X-ray Diffraction - In situ Crystallization - In meso Crystallization - Crystal X-ray Diffraction - Others
By End-User • Pharmaceutical and Biotechnology Companies • Academic and Government Institutes • Contract Research Organizations (CRO) • Others
By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
The market is classified into products and services, technology, application, end user and region. The products and services segment is fragmented into reagents and assay kits, instruments, software and services. The reagents and assay kits segment held the largest high throughput screening market share and this can be credited to an increased used of assay kits and reactors in HTS method, growing occurrences of chronic diseases, increase in the number of research and development activities by pharmaceutical companies, surging assistance from government through massive funding for research in the life sciences sector. However, the software segment is predicted to showcase significant growth during the forecasted timeframe, and this is due to the soaring automation of HTS and the ease of availability of software tools required for data management. The technology segment is divided into cell-based assay which is further divided into 2D cell culture and 3D cell culture, lab-on-a-chip, ultra-high throughput screening, bioinformatics and label-free technology. The label-free technology is predicted to record the highest growth during the forecasted timeframe, and this is primarily due to advancements that have improved the throughput, cost, sensitivity and data analysis level. Using assays that are biologically relevant is the new high throughput screening market trend which shall provide growth opportunities for the market. The end user segment is fragmented into CROs, academic and government institutes, pharmaceutical and biotech companies and other end users. The pharmaceutical and biotech companies are expected to lead the market, and this is due to the in-depth usage of HTS technology in these companies for application related to drug discovery.
Regional Analysis:
The North America region is anticipated to dominate the market owing to a rise in the research and development expenditure provided by the pharma and biotech companies and the increased acceptance of HTS in the region. The Asia Pacific region, however, is poised to showcase substantial growth during the forecast period and this can be credited to a soaring expenditure on research and development, increased private-public collaborations and increased export of services offering drug discovery.
Competitive Landscape:
Some of the key market players are Thermo Fisher Scientific, Agilent Technologies Inc., Danaher , PerkinElmer Inc., Tecan Group Ltd., Axxam S.p.A, Bio-Rad Laboratories Inc, Merck Group KGaA, Hamilton Company, Corning Incorporated, Biotek Instruments Inc., Aurora Biomed Inc.
FutureWise Key Takeaways:
• Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global high throughput screening market by products and services, by technology, by application, by detection method, by end user and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Market Variables, Trends & Scope 4.1 Market Lineage Outlook 4.2 Penetration and Growth Prospect Mapping 4.3 Industry Value Chain Analysis 4.4 Cost Analysis Breakdown 4.5 Technology Overview 4.6 Regulatory Framework on Country Level 4.6.1 Reimbursement Framework 4.6.2 Standards and Compliances 5. Market Overview 5.1 Market Dynamics 5.1.1 Market Driver Analysis 5.1.2 Market Restraint Analysis 5.1.3 Industry Challenges 6. Market Analysis tools 6.1 Industry Analysis - Porter’s 6.1.1 Supplier Power 6.1.2 Buyer Power 6.1.3 Substitution Threat 6.1.4 Threat from new entrants 6.1.5 Competitive Rivalry 6.2 Pestel Analysis 6.2.1 Political Landscape 6.2.2 Environmental Landscape 6.2.3 Social landscape 6.2.4 Technology landscape 6.2.5 Legal Landscape 7. High Throughput Screening Market, By Products and Services Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 7.1 Products 7.1.1 Reagents and Assay Kits 7.1.2 Instruments 7.1.3 Software 7.2 Services 8. Global High Throughput Screening Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Drug Discovery 8.1.1. Medicinal Chemistry 8.1.2. Biology Services 8.1.3. Drug Metabolism and Pharmacokinetics (DMPK) 8.2. Chemical Biology Programs 8.2.1. Cellular & Biological Simulation 8.2.2. Disease Modelling 8.2.3. Preclinical Drug Development 8.2.4. Clinical Trials 8.3. Cell & Organ-Based Screening 8.3.1. Drug Discovery 8.3.2. Academic Research 8.4. Biochemical Screening 8.4.1. Blood and Blood –based Products 8.4.2. Vaccines and Therapeutics 8.4.3. Stem Cells 8.5 Biological Active Compound Screening 8.5.1. Target Identification 8.5.2. Primary Screening 8.5.3. Toxicology 8.6. Genomics 8.6.1. Diagnostic Application 8.6.2. Precision Medicine 8.7. Proteomics 8.7.1. Drug Diagnostics 8.7.2. Precision Medicine 8.8. Compound Profiling 8.8.1. Drug Discovery 8.8.2. Cancer/Tumor Profiling 8.8.3. Toxicology 9. Global High Throughput Screening Market, By Technology Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Cell-Based Assays 9.1.1. Cell Proliferation Assays 9.1.2. Cell Viability Assays 9.1.3. Cell Cytotoxicity Assays 9.1.4. Cell Death Assays 9.1.5. Other Cell Based Assays 9.2. Lab-on-a-Chip 9.2.1. PDMS 9.2.2. Thermopolymers 9.2.3. Glass 9.2.4. Silicon 9.2.5. Paper 9.3. Ultra High Throughput Screening 9.3.1. Chip-based Screening 9.3.2. Micro-channel Flow Systems 9.3.3. Platess Systems 9.3.4. Others 9.4. Label Free Technology 9.4.1. SPR 9.4.2. ITC 9.4.3. Others 10. Global High Throughput Screening Market, By Detection Method Historical Analysis and Forecast 2020-2027 (USD Million) 10.1. Mass Spectroscopy 10.1.1. Surface-based MALDI-MS 10.1.2. LASI-MS Imaging 10.1.3. Injection-based MS 10.1.4. Others 10.2. Chromatography 10.2.1. HIC 10.2.2. HPLC 10.2.3. SEC 10.2.4. HPGC 10.2.5. Others 10.3. Calorimetry 10.3.1. Rapid Mass Calorimeter 10.3.2. ITC 10.3.3. Nanocalorimetry 10.3.4. Array Calorimetry 10.3.5. Others 10.4. X-Ray Diffraction 10.4.1. in situ Crystallization 10.4.2. in meso Crystallization 10.4.3. Crystal X-ray Diffraction 10.4.4. Others 10.5 Others 11. Global High Throughput Screening Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million) 11.1. Pharmaceutical and Biotechnology Companies 11.2. Academic and Government Institutes 11.3. Contract Research Organizations (CRO) 11.4. Others 12. North America High Throughput Screening Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) along with expected regulatory needs 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. U.S.A 12.2.2. Canada 12.2.3. Mexico 12.3. Market Size (USD Million) Forecast for North America 2020-2027 12.4. North America High Throughput Screening Market (2015- 2027) By Application breakdown (Slide 46 to 49) 13. Latin America High Throughput Screening Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Regional Market Trends 13.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.3.1. Brazil 13.3.2. Venezuela 13.3.3. Argentina 13.3.4. Rest of Latin America 13.4. Market Size (USD Million) Forecast for Latin America 2020-2027 14. Europe High Throughput Screening Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Germany 14.2.2. U.K 14.2.3. France 14.2.4. Italy 14.2.5. Spain 14.2.6. Russia 14.2.7. Poland 14.2.8. Switzerland 14.2.9. Netherlands 14.2.10. Rest of Western Europe 14.3. Market Size (USD Million) Forecast for Europe 2020-2027 15. Asia Pacific High Throughput Screening Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 15.2.1. Japan 15.2.2. China 15.2.3. Singapore 15.2.4. India 15.2.5. Australia and New Zealand 15.2.6. ASEAN (Malaysia, Thailand, Indonesia, Philippines and Vietnam) 15.2.7. South Korea 15.2.8. Taiwan 15.2.9. Rest of Asia Pacific 15.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 16. Middle East and Africa High Throughput Screening Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 16.2.1. Saudi Arabia 16.2.2. UAE 16.2.3. South Africa 16.2.4. Egypt 16.3. Market Size (USD Million) Forecast for MEA 2020-2027 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 17.1. Thermo Fisher Scientific 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Agilent Technologies Inc. 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3 Danaher 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. PerkinElmer Inc. 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Tecan Group Ltd. 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Axxam S.p.A 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Bio-Rad Laboratories Inc 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Merck Group KGaA 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Hamilton Company 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10. Corning Incorporated 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11. Biotek Instruments Inc. 17.11.1. Company Overview 17.11.2. Product Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12. Aurora Biomed Inc. 17.12.1. Company Overview 17.12.2. Product Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Market Variables, Trends & Scope 4.1 Market Lineage Outlook 4.2 Penetration and Growth Prospect Mapping 4.3 Industry Value Chain Analysis 4.4 Cost Analysis Breakdown 4.5 Technology Overview 4.6 Regulatory Framework on Country Level 4.6.1 Reimbursement Framework 4.6.2 Standards and Compliances 5. Market Overview 5.1 Market Dynamics 5.1.1 Market Driver Analysis 5.1.2 Market Restraint Analysis 5.1.3 Industry Challenges 6. Market Analysis tools 6.1 Industry Analysis - Porter’s 6.1.1 Supplier Power 6.1.2 Buyer Power 6.1.3 Substitution Threat 6.1.4 Threat from new entrants 6.1.5 Competitive Rivalry 6.2 Pestel Analysis 6.2.1 Political Landscape 6.2.2 Environmental Landscape 6.2.3 Social landscape 6.2.4 Technology landscape 6.2.5 Legal Landscape 7. High Throughput Screening Market, By Products and Services Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 7.1 Products 7.1.1 Reagents and Assay Kits 7.1.2 Instruments 7.1.3 Software 7.2 Services 8. Global High Throughput Screening Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Drug Discovery 8.1.1. Medicinal Chemistry 8.1.2. Biology Services 8.1.3. Drug Metabolism and Pharmacokinetics (DMPK) 8.2. Chemical Biology Programs 8.2.1. Cellular & Biological Simulation 8.2.2. Disease Modelling 8.2.3. Preclinical Drug Development 8.2.4. Clinical Trials 8.3. Cell & Organ-Based Screening 8.3.1. Drug Discovery 8.3.2. Academic Research 8.4. Biochemical Screening 8.4.1. Blood and Blood –based Products 8.4.2. Vaccines and Therapeutics 8.4.3. Stem Cells 8.5 Biological Active Compound Screening 8.5.1. Target Identification 8.5.2. Primary Screening 8.5.3. Toxicology 8.6. Genomics 8.6.1. Diagnostic Application 8.6.2. Precision Medicine 8.7. Proteomics 8.7.1. Drug Diagnostics 8.7.2. Precision Medicine 8.8. Compound Profiling 8.8.1. Drug Discovery 8.8.2. Cancer/Tumor Profiling 8.8.3. Toxicology 9. Global High Throughput Screening Market, By Technology Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Cell-Based Assays 9.1.1. Cell Proliferation Assays 9.1.2. Cell Viability Assays 9.1.3. Cell Cytotoxicity Assays 9.1.4. Cell Death Assays 9.1.5. Other Cell Based Assays 9.2. Lab-on-a-Chip 9.2.1. PDMS 9.2.2. Thermopolymers 9.2.3. Glass 9.2.4. Silicon 9.2.5. Paper 9.3. Ultra High Throughput Screening 9.3.1. Chip-based Screening 9.3.2. Micro-channel Flow Systems 9.3.3. Platess Systems 9.3.4. Others 9.4. Label Free Technology 9.4.1. SPR 9.4.2. ITC 9.4.3. Others
10. Global High Throughput Screening Market, By Detection Method Historical Analysis and Forecast 2020-2027 (USD Million) 10.1. Mass Spectroscopy 10.1.1. Surface-based MALDI-MS 10.1.2. LASI-MS Imaging 10.1.3. Injection-based MS 10.1.4. Others 10.2. Chromatography 10.2.1. HIC 10.2.2. HPLC 10.2.3. SEC 10.2.4. HPGC 10.2.5. Others 10.3. Calorimetry 10.3.1. Rapid Mass Calorimeter 10.3.2. ITC 10.3.3. Nanocalorimetry 10.3.4. Array Calorimetry 10.3.5. Others 10.4. X-Ray Diffraction 10.4.1. in situ Crystallization 10.4.2. in meso Crystallization 10.4.3. Crystal X-ray Diffraction 10.4.4. Others 10.5 Others
11. Global High Throughput Screening Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million) 11.1. Pharmaceutical and Biotechnology Companies 11.2. Academic and Government Institutes 11.3. Contract Research Organizations (CRO) 11.4. Others
12. North America High Throughput Screening Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) along with expected regulatory needs 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. U.S.A 12.2.2. Canada 12.2.3. Mexico 12.3. Market Size (USD Million) Forecast for North America 2020-2027 12.4. North America High Throughput Screening Market (2015- 2027) By Application breakdown (Slide 46 to 49)
13. Latin America High Throughput Screening Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Regional Market Trends 13.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.3.1. Brazil 13.3.2. Venezuela 13.3.3. Argentina 13.3.4. Rest of Latin America 13.4. Market Size (USD Million) Forecast for Latin America 2020-2027
14. Europe High Throughput Screening Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Germany 14.2.2. U.K 14.2.3. France 14.2.4. Italy 14.2.5. Spain 14.2.6. Russia 14.2.7. Poland 14.2.8. Switzerland 14.2.9. Netherlands 14.2.10. Rest of Western Europe 14.3. Market Size (USD Million) Forecast for Europe 2020-2027
15. Asia Pacific High Throughput Screening Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 15.2.1. Japan 15.2.2. China 15.2.3. Singapore 15.2.4. India 15.2.5. Australia and New Zealand 15.2.6. ASEAN (Malaysia, Thailand, Indonesia, Philippines and Vietnam) 15.2.7. South Korea 15.2.8. Taiwan 15.2.9. Rest of Asia Pacific 15.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
16. Middle East and Africa High Throughput Screening Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 16.2.1. Saudi Arabia 16.2.2. UAE 16.2.3. South Africa 16.2.4. Egypt 16.3. Market Size (USD Million) Forecast for MEA 2020-2027
17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 17.1. Thermo Fisher Scientific 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Agilent Technologies Inc. 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3 Danaher 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. PerkinElmer Inc. 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Tecan Group Ltd. 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Axxam S.p.A 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Bio-Rad Laboratories Inc 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Merck Group KGaA 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Hamilton Company 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10. Corning Incorporated 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11. Biotek Instruments Inc. 17.11.1. Company Overview 17.11.2. Product Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12. Aurora Biomed Inc. 17.12.1. Company Overview 17.12.2. Product Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview
18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations
19. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics